NYSE:ENFN Enfusion (ENFN) Stock Price, News & Analysis $8.20 0.00 (0.00%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$8.16▼$8.2250-Day Range$7.89▼$9.7052-Week Range$7.52▼$10.45Volume16,249 shsAverage Volume377,062 shsMarket Capitalization$1.05 billionP/E Ratio273.42Dividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enfusion alerts: Email Address Enfusion MarketRank™ Stock AnalysisAnalyst RatingReduce1.67 Rating ScoreUpside/Downside14.0% Upside$9.33 Price TargetShort InterestHealthy3.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$296,688 Sold Last QuarterProj. Earnings Growth122.22%From $0.09 to $0.20 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.62 out of 5 starsComputer And Technology Sector319th out of 594 stocksPrepackaged Software Industry107th out of 197 stocks 1.8 Analyst's Opinion Consensus RatingEnfusion has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on 1 buy rating, 2 hold ratings, and 3 sell ratings.Amount of Analyst CoverageEnfusion has received no research coverage in the past 90 days.Read more about Enfusion's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.98% of the float of Enfusion has been sold short.Short Interest Ratio / Days to CoverEnfusion has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Enfusion has recently decreased by 17.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnfusion does not currently pay a dividend.Dividend GrowthEnfusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENFN. Previous Next 1.1 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Enfusion this week, compared to 2 articles on an average week.Search Interest1 people have searched for ENFN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Enfusion to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enfusion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $296,688.00 in company stock.Percentage Held by Insiders36.44% of the stock of Enfusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.05% of the stock of Enfusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enfusion's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Enfusion are expected to grow by 122.22% in the coming year, from $0.09 to $0.20 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enfusion is 273.09, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Enfusion is 273.09, which means that it is trading at a less expensive P/E ratio than the Computer and Technology sector average P/E ratio of about 284.69.Price to Earnings Growth RatioEnfusion has a PEG Ratio of 2.15. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEnfusion has a P/B Ratio of 13.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enfusion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Strange Disappearance of MILLIONS of American JobsA former hedge fund manager who bought Apple at a split-adjusted 35 cents and Amazon at $2.40 (split adjusted) just went issued a major warning.You can watch our interview, here, free of charge. About Enfusion Stock (NYSE:ENFN)Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.Read More ENFN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENFN Stock News HeadlinesAugust 19 at 4:00 PM | globenewswire.comEnfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsAugust 17, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFNAugust 22, 2024 | DTI (Ad)Air Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10.August 14, 2024 | finance.yahoo.comInvestors Can Find Comfort In Enfusion's (NYSE:ENFN) Earnings QualityAugust 12, 2024 | prnewswire.comENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law FirmAugust 11, 2024 | seekingalpha.comEnfusion, Inc. (ENFN) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | tmcnet.comENFN Investors Have Opportunity to Join Enfusion, Inc. Securities Fraud Investigation with the Schall Law FirmAugust 9, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFNAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 8, 2024 | finance.yahoo.comEnfusion (NYSE:ENFN) Might Be Having Difficulty Using Its Capital EffectivelyAugust 8, 2024 | markets.businessinsider.comMorgan Stanley Keeps Their Buy Rating on Enfusion (ENFN)August 6, 2024 | finance.yahoo.comEnfusion Announces Second Quarter 2024 ResultsAugust 3, 2024 | finance.yahoo.comEnfusion Introduces the Next Phase of Portfolio Workbench, Empowering Asset Managers with Increased Efficiency and FlexibilityJuly 20, 2024 | finance.yahoo.comEnfusion, Inc. (ENFN)June 15, 2024 | seekingalpha.comEnfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy RatingJune 13, 2024 | businesswire.comFTV Capital Expands Internationally with Opening of London OfficeMay 29, 2024 | businesswire.comEnfusion To Present at Upcoming Investor EventsMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enfusion on Strong Growth and Market Positioning ProspectsSee More Headlines Receive ENFN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enfusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorComputer and Technology Industry Prepackaged software Sub-IndustryN/A Current SymbolNYSE:ENFN CUSIPN/A CIK1868912 Webwww.enfusion.com Phone312-253-9800FaxN/AEmployees1,102Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$11.00 Low Stock Price Target$8.00 Potential Upside/Downside+14.0%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio273.09 Forward P/E Ratio91.00 P/E Growth2.15Net Income$6.03 million Net Margins1.40% Pretax Margin3.04% Return on Equity6.60% Return on Assets4.86% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual Sales$188.35 million Price / Sales5.57 Cash Flow$0.13 per share Price / Cash Flow64.11 Book Value$0.61 per share Price / Book13.43Miscellaneous Outstanding Shares128,110,000Free Float81,427,000Market Cap$1.05 billion OptionableOptionable Beta0.92 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Oleg Movchan (Age 49)CEO & Director Comp: $876.34kMr. Bradley Herring (Age 53)Chief Financial Officer Comp: $267.05kMs. Bronwen Bastone (Age 51)Chief People Officer Comp: $566.25kMr. Stephen MalherbeManaging PartnerMs. Valeria Gutowski (Age 42)Chief Accounting Officer Mr. Daniel Groman (Age 35)Chief Technology Officer Mr. Ignatius Tochukwu NjokuHead of Investor RelationsMr. Joseph DefeoGlobal Head of Managed Services ProductionMr. Jeff YoungHead of ImplementationMr. Robert TaylorHead of Client SupportMore ExecutivesKey CompetitorsClear SecureNYSE:YOUBOXNYSE:BOXBlackbaudNASDAQ:BLKBnCinoNASDAQ:NCNOFreshworksNASDAQ:FRSHView All CompetitorsInsiders & InstitutionsClearline Capital LPSold 70,738 shares on 8/16/2024Ownership: 0.143%Susquehanna Fundamental Investments LLCBought 11,116 shares on 8/15/2024Ownership: 0.019%Mackenzie Financial CorpBought 22,517 shares on 8/15/2024Ownership: 0.018%AQR Capital Management LLCSold 36,554 shares on 8/15/2024Ownership: 0.016%The Manufacturers Life Insurance Company Bought 4,239 shares on 8/15/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions ENFN Stock Analysis - Frequently Asked Questions How have ENFN shares performed this year? Enfusion's stock was trading at $9.70 at the beginning of the year. Since then, ENFN stock has decreased by 15.6% and is now trading at $8.19. View the best growth stocks for 2024 here. How were Enfusion's earnings last quarter? Enfusion, Inc. (NYSE:ENFN) posted its earnings results on Thursday, May, 9th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.04 by $0.05. The company earned $48.05 million during the quarter, compared to analysts' expectations of $47.67 million. Enfusion had a net margin of 1.40% and a trailing twelve-month return on equity of 6.60%. When did Enfusion IPO? Enfusion (ENFN) raised $300 million in an IPO on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $15.00-$17.00 per share. Who are Enfusion's major shareholders? Enfusion's top institutional investors include Scalar Gauge Management LLC (0.48%), Dimensional Fund Advisors LP (0.41%), Clearline Capital LP (0.14%) and Bank of New York Mellon Corp (0.12%). Insiders that own company stock include Oleg Movchan, Bronwen Bastone, Dan Groman, Matthew Campobasso, Deirdre Somers, Valeria Gutowski, Tarek Hammoud, Stephen Malherbe, Hillhouse Investment Managemen and Roy Luo. View institutional ownership trends. How do I buy shares of Enfusion? Shares of ENFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENFN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enfusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enfusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENFN Stock Alerts